Peter  Lamb net worth and biography

Peter Lamb Biography and Net Worth

EVP of Exelixis
Peter Lamb, Ph.D., has served as Executive Vice President, Scientific Strategy and Chief Scientific Officer since February 2016. Previously, he served as Executive Vice President, Discovery Research and Chief Scientific Officer from September 2009 to February 2016, as Senior Vice President, Discovery Research and Chief Scientific Officer from January 2007 until September 2009, as Vice President, Discovery Pharmacology from December 2003 until January 2007 and as Senior Director, Molecular Pharmacology and Structural Biology from October 2000 until December 2003. Prior to joining Exelixis, from June 1992 until September 2000, Dr. Lamb held positions of increasing responsibility at Ligand Pharmaceuticals, a pharmaceutical company, most recently serving as Director of Transcription Research. Dr. Lamb has held post-doctoral research fellowships at the Carnegie Institution, Department of Embryology, with Dr. S.L. McKnight and the University of Oxford with Dr. N.J. Proudfoot, working in the field of gene regulation. He has authored numerous articles in the fields of gene expression, signal transduction and oncology, and is an author on multiple issued and pending U.S. patents. He has a Ph.D. in Molecular Biology from the ICRF/University of London and a B.A. in Biochemistry from the University of Cambridge.

What is Peter Lamb's net worth?

The estimated net worth of Peter Lamb is at least $9.78 million as of December 15th, 2022. Dr. Lamb owns 410,958 shares of Exelixis stock worth more than $9,780,800 as of March 28th. This net worth evaluation does not reflect any other investments that Dr. Lamb may own. Additionally, Dr. Lamb receives an annual salary of $909,460.00 as EVP at Exelixis. Learn More about Peter Lamb's net worth.

How old is Peter Lamb?

Dr. Lamb is currently 63 years old. There are 5 older executives and no younger executives at Exelixis. The oldest executive at Exelixis is Dr. Stelios Papadopoulos Ph.D., Co-Founder & Chair of the Board, who is 76 years old. Learn More on Peter Lamb's age.

What is Peter Lamb's salary?

As the EVP of Exelixis, Inc., Dr. Lamb earns $909,460.00 per year. There are 3 executives that earn more than Dr. Lamb. The highest earning executive at Exelixis is Dr. Michael M. Morrissey Ph.D., CEO, President & Director, who commands a salary of $2,310,000.00 per year. Learn More on Peter Lamb's salary.

How do I contact Peter Lamb?

The corporate mailing address for Dr. Lamb and other Exelixis executives is 1851 Harbor Bay Parkway, Alameda CA, 94502. Exelixis can also be reached via phone at (650) 837-7000 and via email at [email protected]. Learn More on Peter Lamb's contact information.

Has Peter Lamb been buying or selling shares of Exelixis?

Peter Lamb has not been actively trading shares of Exelixis in the last ninety days. Most recently, Peter Lamb sold 20,000 shares of the business's stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $15.88, for a transaction totalling $317,600.00. Following the completion of the sale, the executive vice president now directly owns 410,958 shares of the company's stock, valued at $6,526,013.04. Learn More on Peter Lamb's trading history.

Who are Exelixis' active insiders?

Exelixis' insider roster includes Dana Aftab (EVP), Charles Cohen (Director), Carl Feldbaum (Director), Alan Garber (Director), Patrick Haley (EVP), Jeffrey Hessekiel (EVP), David Johnson (Director), Peter Lamb (EVP), Vincent Marchesi (Director), Michael Morrissey (CEO), Stelios Papadopoulos (Director), George Poste (Director), Gisela Schwab (CMO), Christopher Senner (CFO), Lance Willsey (Director), and Jack Wyszomierski (Director). Learn More on Exelixis' active insiders.

Are insiders buying or selling shares of Exelixis?

In the last year, Exelixis insiders bought shares 2 times. They purchased a total of 310,409 shares worth more than $6,535,038.49. In the last year, insiders at the biotechnology company sold shares 11 times. They sold a total of 370,167 shares worth more than $7,895,362.66. The most recent insider tranaction occured on March, 21st when Director Alan M Garber sold 19,205 shares worth more than $461,112.05. Insiders at Exelixis own 2.9% of the company. Learn More about insider trades at Exelixis.

Information on this page was last updated on 3/21/2024.

Peter Lamb Insider Trading History at Exelixis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2022Sell20,000$15.88$317,600.00410,958View SEC Filing Icon  
12/15/2021Sell47,500$17.44$828,400.00View SEC Filing Icon  
11/15/2021Sell47,500$18.09$859,275.00View SEC Filing Icon  
10/15/2021Sell47,500$21.92$1,041,200.00View SEC Filing Icon  
8/16/2021Sell55,000$18.44$1,014,200.00View SEC Filing Icon  
7/15/2021Sell60,000$17.47$1,048,200.00View SEC Filing Icon  
6/17/2021Sell60,000$22.18$1,330,800.00View SEC Filing Icon  
4/1/2021Sell60,000$22.96$1,377,600.00View SEC Filing Icon  
3/1/2021Sell65,000$22.11$1,437,150.00View SEC Filing Icon  
2/1/2021Sell65,000$22.08$1,435,200.00View SEC Filing Icon  
1/4/2021Sell65,000$20.32$1,320,800.00View SEC Filing Icon  
12/18/2020Sell65,000$20.01$1,300,650.00View SEC Filing Icon  
6/8/2020Sell26,000$22.56$586,560.00View SEC Filing Icon  
4/6/2020Sell50,000$17.26$863,000.00View SEC Filing Icon  
6/17/2019Sell217,404$20.59$4,476,348.36View SEC Filing Icon  
6/13/2019Sell27,596$20.03$552,747.88View SEC Filing Icon  
1/3/2017Sell70,000$14.65$1,025,500.00View SEC Filing Icon  
12/1/2016Sell70,000$16.66$1,166,200.00View SEC Filing Icon  
10/16/2015Sell51,549$5.80$298,984.2036,473View SEC Filing Icon  
10/13/2015Sell600$5.80$3,480.0036,473View SEC Filing Icon  
10/12/2015Sell300,276$5.84$1,753,611.8436,473View SEC Filing Icon  
See Full Table

Peter Lamb Buying and Selling Activity at Exelixis

This chart shows Peter Lamb's buying and selling at Exelixis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Exelixis Company Overview

Exelixis logo
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Read More

Today's Range

Now: $23.73
Low: $22.70
High: $23.98

50 Day Range

MA: $22.02
Low: $20.17
High: $23.92

2 Week Range

Now: $23.73
Low: $18.08
High: $24.34

Volume

2,953,471 shs

Average Volume

2,365,561 shs

Market Capitalization

$7.19 billion

P/E Ratio

37.08

Dividend Yield

N/A

Beta

0.53